A Study of Pioglitazone and Carboplatin in Patients With Advanced Solid Tumors
NCT02133625
Completed
The proposed investigation is a Phase 1 trial to determine the safety, tolerability, and maximum tolerated dose (MTD) of the combination of pioglitazone ( and carboplatin patients with advanced or metastatic solid malignancies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2016
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts +1 locations
Conditions: Advanced Solid Tumor, Metastatic Solid Tumor
Register for Updates
Carboplatin, Pemetrexed, and Panitumumab in Patients With Advanced Non-Squamous K-ras Wild Type NSCLC
NCT01042288
Completed
The purpose of this multicenter, Phase II trial is to examine the role of a well-tolerated novel agent, panitumumab, in combination with a modern platinum doublet regimen using carboplatin and pemetrexed, in patients with advanced non-squamous wild type K-ras non-small-cell lung cancer (NSCLC). If this treatment proves to be well tolerated and associated with efficacy, this would provide rationale for further randomized studies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2016
Locations: Florida Cancer Specialists, Ft. Myers, Florida +12 locations
Conditions: Non-Small-Cell Lung Cancer
Register for Updates
Phase II Study of ZD6474 in Advanced NSCLC
NCT00290537
Terminated
The goal of this clinical research study is to learn how the drug ZD6474 affects the amount of tumor cell death in the body and the amount of blood that can be supplied to the tumor. The safety of ZD6474 alone and when given with chemotherapy will be studied. In addition, the side effects and response to this treatment will also be studied.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/13/2016
Locations: University of Texas M.D.Anderson Cancer Center, Houston, Texas
Conditions: Lung Cancer
Register for Updates
Paclitaxel, Ifosfamide, and Carboplatin Followed By Autologous Stem Cell Transplant in Treating Patients With Germ Cell Tumors That Did Not Respond to Cisplatin
NCT00423852
Completed
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, ifosfamide, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. An autologous peripheral stem cell transplant may be able to replace blood-forming cells that were destroyed by chemotherapy. This may allow more chemotherapy to be given so that more tumor cells are killed. PU... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
04/12/2016
Locations: Memorial Sloan-Kettering Cancer Center, New York, New York
Conditions: Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Ovarian Cancer, Teratoma, Testicular Germ Cell Tumor
Register for Updates
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors
NCT00002558
Completed
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, ifosfamide, carboplatin, and etoposide work in different ways to stop the growth of tumor cells, either by killing them or by stopping them from dividing. Giving chemotherapy with a peripheral stem cell transplant may allow more chemotherapy to be given so that more tumor cells are killed. The design of this trial is a phase I/II trial of sequential accelerated chemotherapy cycles with taxol/ifosfamide and carboplatin/etoposide administ... Read More
Gender:
ALL
Ages:
15 years and above
Trial Updated:
04/11/2016
Locations: Memorial Sloan-Kettering Cancer Center, New York, New York
Conditions: Extragonadal Germ Cell Tumor, Ovarian Cancer, Testicular Germ Cell Tumor
Register for Updates
Paclitaxel and Carboplatin in Women With Malignant Mixed Mullerian Tumors (MMMT) of the Uterus
NCT00502203
Completed
The goal of this clinical research study is to find out if the combination of paclitaxel and carboplatin chemotherapy can shrink or slow the growth of mixed mullerian tumors (MMMT) of the uterus.
Gender:
FEMALE
Ages:
All
Trial Updated:
04/05/2016
Locations: Loma Linda Cancer Institute, Loma Linda, California +3 locations
Conditions: Mixed Tumor, Mullerian
Register for Updates
Tarceva Surgery for Resectable Stage IIIA(N2) and IIIB (T4 N2) Non-Small-Cell Lung Cancer
NCT00063258
Terminated
The goal of this clinical research study is to learn about the safety and effectiveness of OSI-774 when combined with standard chemotherapy (carboplatin and paclitaxel) before surgery in the treatment of non-small cell lung cancer.
Gender:
ALL
Ages:
All
Trial Updated:
04/05/2016
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Lung Cancer
Register for Updates
A Trial of Amrubicin and Carboplatin With Pegfilgrastim in Patients With Extensive-Stage Small Cell Lung Cancer
NCT01076504
Completed
This proposed trial will investigate the combination of amrubicin and carboplatin in the first-line treatment of patients with extensive-stage small cell lung cancer (ES- SCLC). Since myelosuppression is the most common toxicity produced by this drug combination, pegfilgrastim will be administered with each treatment cycle. This trial will be the first clinical trial to evaluate a combination of amrubicin and carboplatin in the first-line treatment of ES SCLC in a U.S. population.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/01/2016
Locations: Northeast Arkansas Clinic, Jonesboro, Arkansas +19 locations
Conditions: Extensive-Stage Small Cell Lung Cancer
Register for Updates
A Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the Lung
NCT00998192
Completed
The purpose of this Phase 2 study is to investigate whether intravenous administration of REOLYSIN therapeutic reovirus in combination with paclitaxel and carboplatin is effective and safe in the treatment of squamous cell carinoma of the lung.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/29/2016
Locations: Cedars-Sinai Medical Center, Los Angeles, California +16 locations
Conditions: Metastatic or Recurrent Squamous Cell Carcinoma of the Lung
Register for Updates
A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas
NCT00995007
Completed
Background: * Growth of new blood vessels (angiogenesis) provides many tumors, including brain tumors, with needed nutrients and oxygen for cancer cells to survive. One possible treatment for different kinds of cancer involves treatment with drugs that slow or stop angiogenesis and prevent further tumor growth. * Vandetanib is an oral medication known to block angiogenesis and has shown significant antitumor activity in laboratory and animal studies. Vandetanib appears to be well tolerated by p... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
02/25/2016
Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland
Conditions: Glioblastoma Multiforme, Gliosarcoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Mixed Oligoastrocytoma
Register for Updates
Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC)
NCT01082549
Completed
To evaluate the overall survival (OS) of patients with advanced squamous cell lung cancer receiving the combination of gemcitabine/carboplatin either with or without Iniparib. Based on data generated by BiPar/Sanofi, it is concluded that iniparib does not possess characteristics typical of the PARP inhibitor class. The exact mechanism has not yet been fully elucidated, however based on experiments on tumor cells performed in the laboratory, iniparib is a novel investigational anti-cancer agent... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/17/2016
Locations: Investigational Site Number 840306, Birmingham, Alabama +141 locations
Conditions: Squamous Cell Lung Cancer
Register for Updates
A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer
NCT00813956
Completed
This study will investigate whether the neoadjuvant combination of gemcitabine, carboplatin, and BSI-201 will cause a high percentage of triple negative breast cancer patients to achieve a pathologic complete response prior to surgery. Based on data generated by BiPar/Sanofi, it is concluded that iniparib does not possess characteristics typical of the PARP inhibitor class. The exact mechanism has not yet been fully elucidated, however based on experiments on tumor cells performed in the labora... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/17/2016
Locations: Stanford Comprehensive Cancer Center, Stanford, California +1 locations
Conditions: Triple Negative Breast Cancer
Register for Updates